<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>PaMZ – TB</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/>      <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
     <!-- Compiled and minified CSS -->
     <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/materialize/1.0.0/css/materialize.min.css"></head><body>  <ul class="center notranslate"> <li id="answerSpeak" class="col s2"><a  href="javascript:answerSpeak()"><i id="answerSpeakI" class="small orange-text material-icons">play_circle_filled</i></a></li><li class="col s2"><a href="javascript:resumeSpeak()"><i id="pause-resume" class="small pink-text material-icons noDisplay">pause</i></a></li>  <li id="backL" class="col s2 "><a  href="javascript:goBack()"><i id="back" class="small orange-text material-icons">navigate_before</i></a></li> <li id="forwardL" class="col s2 "><a  href="javascript:goForward()"><i id="forward" class="small orange-text material-icons">navigate_next</i></a></li><div id="google_translate_element"></div></ul><p class="top_nav"  ><a href="part452.htm">&lt; Previous</a><span> | </span><a href="../index.html">Contents</a><span> | </span><a href="part454.htm">Next &gt;</a></p>  <p  style="padding-top: 1pt;padding-left: 15pt;text-indent: 0pt;text-align: left;">PaMZ – TB </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s4" style="padding-left: 51pt;text-indent: -18pt;text-align: justify;"><span class="s5"> </span><span class="p">PaMZ – TB is new tuberculosis (TB) drug developed by Global Alliance for TB Drug Development (TB Alliance).</span></p><p class="s4" style="padding-left: 51pt;text-indent: -18pt;text-align: justify;"><span class="s5"> </span><span class="p">PaMZ is a combination of three drugs, two of which have not been licensed for TB treatment before. If the trials are conclusive, it will only be the third new TB drug to be licensed in 60 years.</span></p><p style="padding-left: 51pt;text-indent: -18pt;text-align: justify;"><span class="s4"></span><span class="s5"> </span>PaMZ’s development has been<u> </u><u><b>hailed as abreakthrough</b></u>. It will be available for both drug-sensitive and some drug resistant TB patients (about a third of cases). In the case of the latter, it promises to reduce the treatment duration (from two years to six months) and its cost (from $2,000 to $100), simplify it (pills-only, no injection required) and improve cure rates.</p><p style="text-indent: 0pt;text-align: left;"><span><img class="responsive-img"  width="95%" height="auto"  alt=" " onerror='this.style.display="none"'  src="Image_228.png"/></span></p><p class="s4" style="padding-left: 51pt;text-indent: -18pt;text-align: justify;"><span class="s5"> </span><span class="p">PaMZ will also be compatible with anti-retrovirals (ARV) for treating HIV, offering a new solution for millions of co-infected HIV-TB patients. At least a third of the 35.3m people living with HIV are infected with TB and the disease is the leading cause of death among HIV-positive patients.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part452.htm">&lt; Previous</a><span> | </span><a href="../index.html">Contents</a><span> | </span><a href="part454.htm">Next &gt;</a></p><p class="nav">&nbsp;&nbsp; </p><script src="index.js"></script>
<script type="text/javascript" src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/materialize/1.0.0/js/materialize.min.js"></script></body></html>
